JP2018536620A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536620A5
JP2018536620A5 JP2018506141A JP2018506141A JP2018536620A5 JP 2018536620 A5 JP2018536620 A5 JP 2018536620A5 JP 2018506141 A JP2018506141 A JP 2018506141A JP 2018506141 A JP2018506141 A JP 2018506141A JP 2018536620 A5 JP2018536620 A5 JP 2018536620A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
mdsc
composition according
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018506141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536620A (ja
JP6927499B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/045739 external-priority patent/WO2017024213A1/en
Publication of JP2018536620A publication Critical patent/JP2018536620A/ja
Publication of JP2018536620A5 publication Critical patent/JP2018536620A5/ja
Priority to JP2021118749A priority Critical patent/JP7235259B2/ja
Application granted granted Critical
Publication of JP6927499B2 publication Critical patent/JP6927499B2/ja
Priority to JP2023021455A priority patent/JP2023053338A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018506141A 2015-08-06 2016-08-05 Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節 Active JP6927499B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021118749A JP7235259B2 (ja) 2015-08-06 2021-07-19 Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節
JP2023021455A JP2023053338A (ja) 2015-08-06 2023-02-15 Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201990P 2015-08-06 2015-08-06
US62/201,990 2015-08-06
PCT/US2016/045739 WO2017024213A1 (en) 2015-08-06 2016-08-05 Modulating inflammasome activation of myeloid-derived supperssor cells for treating gvhd or tumor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021118749A Division JP7235259B2 (ja) 2015-08-06 2021-07-19 Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節

Publications (3)

Publication Number Publication Date
JP2018536620A JP2018536620A (ja) 2018-12-13
JP2018536620A5 true JP2018536620A5 (OSRAM) 2019-09-05
JP6927499B2 JP6927499B2 (ja) 2021-09-01

Family

ID=56686964

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018506141A Active JP6927499B2 (ja) 2015-08-06 2016-08-05 Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節
JP2021118749A Active JP7235259B2 (ja) 2015-08-06 2021-07-19 Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節
JP2023021455A Pending JP2023053338A (ja) 2015-08-06 2023-02-15 Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021118749A Active JP7235259B2 (ja) 2015-08-06 2021-07-19 Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節
JP2023021455A Pending JP2023053338A (ja) 2015-08-06 2023-02-15 Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節

Country Status (9)

Country Link
US (2) US10894061B2 (OSRAM)
EP (3) EP3682889B1 (OSRAM)
JP (3) JP6927499B2 (OSRAM)
CN (2) CN114790447A (OSRAM)
AU (2) AU2016303622B2 (OSRAM)
CA (1) CA2993806A1 (OSRAM)
ES (2) ES2939534T3 (OSRAM)
PT (1) PT3682889T (OSRAM)
WO (1) WO2017024213A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2993806A1 (en) 2015-08-06 2017-02-09 Regents Of The University Of Minnesota Modulating inflammasome activation of myeloid-derived supperssor cells for treating gvhd or tumor
FR3100715B1 (fr) * 2019-09-12 2023-09-29 Francais Du Sang Ets Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte
WO2022216615A1 (en) * 2021-04-05 2022-10-13 Rhode Island Hospital Compositions and methods for the prevention or treatment of rheumatoid arthritis
CN113707223A (zh) * 2021-04-21 2021-11-26 吴安华 一种预测肿瘤炎性小体活性状态及治疗敏感性的基因集系统及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136973A1 (en) 2002-11-07 2004-07-15 Eliezer Huberman Human stem cell materials and methods
EP2300000A1 (en) 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
US20120082688A1 (en) * 2008-11-26 2012-04-05 Mount Sinai School Of Medicine In Vitro Generation of Myeloid Derived Suppressor Cells
EP2515919A2 (en) * 2009-12-22 2012-10-31 Mount Sinai School of Medicine Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases
US20140377278A1 (en) 2012-01-10 2014-12-25 Yale University Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders
AR095882A1 (es) * 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
WO2015016178A1 (ja) 2013-07-29 2015-02-05 国立大学法人鹿児島大学 １，５－ｄ－アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬
MX393750B (es) * 2014-12-31 2025-03-24 Checkmate Pharmaceuticals Inc Inmunoterapia antitumoral combinada.
PL3656443T3 (pl) * 2015-01-21 2022-01-31 The Board Of Trustees Of The Leland Stanford Junior University Zastosowanie agonisty trl i środka anty-cd47 do wzmocnienia fagotocytozy komórek nowotworowych
CA2993806A1 (en) * 2015-08-06 2017-02-09 Regents Of The University Of Minnesota Modulating inflammasome activation of myeloid-derived supperssor cells for treating gvhd or tumor
US11047114B2 (en) 2015-11-13 2021-06-29 Qf Technologies As Method and device to collect water
GB201721185D0 (en) * 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
CN112646777B (zh) * 2020-12-31 2022-11-04 广州医科大学 一种扩增髓系来源的抑制性细胞的方法

Similar Documents

Publication Publication Date Title
BR112013023724A2 (pt) métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento
JP2018536620A5 (OSRAM)
MX2020008208A (es) Agentes de unión a fibroblastos y uso de estos.
JP2016540785A5 (OSRAM)
BR112012024590A2 (pt) métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
CN110114083A (zh) 一种预防和治疗脂肪肝的方法
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EP4276114A3 (en) Cd20 binding single domain antibodies
WO2015103438A3 (en) Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2017177179A9 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
MA48486A (fr) Polymères liant les protons pour administration orale
JP2016530233A5 (OSRAM)
WO2015191934A3 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
Omura‐Matsuoka et al. Hypertension impairs leptomeningeal collateral growth after common carotid artery occlusion: restoration by antihypertensive treatment
MX2019012051A (es) Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
JP2015514756A5 (OSRAM)
CN110062628A (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
JP2018503685A5 (OSRAM)
MX394623B (es) Tecnología de sinergismo anticuerpo-fármaco para el tratamiento de enfermedades.
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
BR112017018963A2 (pt) método para tratar anemia por deficiência de ferro
BR112018000383A2 (pt) métodos para tratar hcv
EP4371610A3 (en) Topical treatment of inflammatory bowel disease using antibodies and fragments thereof
WO2020060779A3 (en) Methods and compositions for treating laminopathies affecting skeletal or cardiac muscle